Noninvasive sequencing is faster, cheaper and safer for mother and fetus, say researchers
Chromosomal abnormalities that result in birth defects and genetic disorders like Down syndrome remain a significant health burden in the United States and throughout the world, with some current prenatal screening procedures invasive and a potential risk to mother and unborn child.
In a paper published online this week in the Early Edition of PNAS, a team of scientists at the University of California, San Diego School of Medicine and in China describe a new benchtop semiconductor sequencing procedure and newly developed bioinformatics software tools that are fast, accurate, portable, less expensive and can be completed without harm to mother or fetus.
"We believe this approach could become the standard of care for screening of prenatal chromosomal abnormalities," said Kang Zhang, MD, PhD, professor of ophthalmology, founding director of the Institute for Genomic Medicine at UC San Diego and a staff physician at the San Diego VA Healthcare System.
The incidence of chromosomal abnormalities – in numbers or structure – is one in 160 live births in the United States, higher in other countries. In China, for example, the rate is one in 60 live births. The effects of these abnormalities, known as aneuploidies, can be severe, from developmental delays and neurological disorders to infertility and death. The incidence rate rises with maternal age, most notably after age 35.
Current diagnoses of fetal aneuploidies often rely upon invasive tests that sample amniotic fluid or placental tissues for fetal DNA that can then be analyzed using a variety of complex and expensive methods, including full karyotyping in which the entire set of chromosomes is viewed microscopically. While highly reliable, these invasive tests may cause infections in the pregnant woman and pose as much as a 1 percent risk of miscarriage and fetal loss. Results are not available for one to two weeks, extending anxiety for families waiting for information.
The new method relies upon massively parallel sequencing of cell-free fetal DNA using a benchtop semiconductor sequencing platform (SSP) called an Ion Torrent sequencer developed by Life Technologies. Cell-free fetal DNA is genetic material from the fetus that circulates naturally and freely in the mother's bloodstream. It can be obtained through an ordinary blood draw, with SSP analysis achieved in less than four days.
To assess the SSP method, researchers tested 2,275 pregnant women. More than 500 participated in a retrospective analysis, undergoing full karyotyping to establish known chromosomal abnormalities followed by SSP testing. The remainder participated in a prospective study without prior karyotyping, and SSP testing results were then compared to karyotyping results. The sequencing and automated bioinformatics analyses were performed at iGenomics in Guangzhou, China.
"We used the retrospective study to establish the method and the prospective study to validate it," said Zhang.
In the retrospective study, the researchers found that SSP detected multiple types of chromosomal abnormality with virtually 100 percent sensitivity and specificity compared to full karyotyping.
"To our knowledge, this is the first large-scale clinical study to systematically identify chromosomal aneuploidies based on cell-free fetal DNA using SSP," said Zhang. "It provides an effective strategy for large-scale, noninvasive screenings in a clinical setting. It can be done in hospitals and outpatient clinics, more quickly and cheaply."
Co-authors are Can Liao, Fang Fu, Ru Li, Yong-ling Zhang, Yan-mei Ou, Jian Li and Dong-zhi Li, Guangzhou Medical University, China; Ai-hua Yi, Jie-xia Yang, Jing Wu, Ming-qin Mai and Xiao-zhuang Zhang, Guangdong Women and Children Hospital, China; Chun-fang Peng, Yang-yi Chen, Dong-hong Luo and Hai-liang Liu, iGenomics Co., Guangzhou, China; Rui Hou, Guangzhou Kang Rui Biological Pharmaceutical Technology Co, Guangzhou, China; Frances Wu, UCSD Institute for Genomic Medicine and UCSD Department of Ophthalmology; and Hongrong Luo, UCSD Institute for Genomic Medicine and UCSD Department of Ophthalmology and Sichuan University, China.
Funding for this research came, in part, from the National Natural Science Foundation of China, National Science Foundation for Young Scholars of China, National Natural Science Foundation of Guangdong, Key Project of Guangzhou Health Bureau, Major Project of Guangzhou Science and Technology and Information Bureau, 973 program and Burroughs Wellcome Fund.
Scott LaFee | Eurek Alert!
Hepatitis: liver failure attributable to compromised blood supply
19.12.2018 | Technische Universität München
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Information Technology
19.12.2018 | Physics and Astronomy
19.12.2018 | Life Sciences